AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Miracle Mile Advisors LLC

Miracle Mile Advisors LLC raised its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 8.1% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 7,614 shares of the company’s stock after purchasing an additional 572 shares during the quarter. Miracle Mile Advisors LLC’s holdings in AstraZeneca were worth $516,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of AZN. Anchor Investment Management LLC acquired a new stake in AstraZeneca during the 4th quarter valued at approximately $26,000. Compagnie Lombard Odier SCmA acquired a new stake in AstraZeneca during the 4th quarter valued at approximately $27,000. Able Wealth Management LLC acquired a new stake in AstraZeneca during the 4th quarter valued at approximately $27,000. Pin Oak Investment Advisors Inc. grew its stake in AstraZeneca by 468.4% during the 4th quarter. Pin Oak Investment Advisors Inc. now owns 449 shares of the company’s stock valued at $30,000 after purchasing an additional 370 shares in the last quarter. Finally, Northwest Financial Advisors acquired a new stake in AstraZeneca during the 4th quarter valued at approximately $34,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Trading Down 0.1 %

Shares of NASDAQ AZN opened at $77.94 on Tuesday. The company has a market cap of $241.65 billion, a price-to-earnings ratio of 38.21, a price-to-earnings-growth ratio of 1.40 and a beta of 0.45. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $80.86. The company has a current ratio of 0.89, a quick ratio of 0.70 and a debt-to-equity ratio of 0.73. The stock’s 50 day simple moving average is $77.68 and its 200 day simple moving average is $70.51.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings results on Thursday, April 25th. The company reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.08. The business had revenue of $12.68 billion for the quarter, compared to the consensus estimate of $11.92 billion. AstraZeneca had a return on equity of 30.42% and a net margin of 13.30%. Equities research analysts expect that AstraZeneca PLC will post 4.04 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on AZN. Barclays upgraded AstraZeneca to a “strong-buy” rating in a research note on Monday, June 24th. Argus increased their target price on AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, May 30th. Citigroup raised AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. The Goldman Sachs Group assumed coverage on AstraZeneca in a report on Thursday, May 30th. They set a “buy” rating and a $97.00 target price on the stock. Finally, BMO Capital Markets increased their target price on AstraZeneca from $80.00 to $82.00 and gave the stock an “outperform” rating in a report on Friday, April 26th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and three have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $88.00.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.